Patrys Limited (PAB.AX) Stock Competitors & Peer Comparison
See (PAB.AX) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PAB.AX | A$0.04 | -7.69% | 12.6M | -3.12 | -A$0.01 | N/A |
| CSL.AX | A$114.49 | -0.33% | 55.3B | 12.41 | A$9.30 | +3.69% |
| TLX.AX | A$16.52 | +7.76% | 5.5B | -583.54 | -A$0.03 | N/A |
| MSB.AX | A$1.94 | +3.02% | 2.5B | -13.11 | -A$0.15 | N/A |
| NEU.AX | A$17.57 | +44.02% | 2.1B | 70.67 | A$0.23 | N/A |
| PYC.AX | A$1.70 | +10.75% | 962M | -36.18 | -A$0.05 | N/A |
| OPT.AX | A$0.60 | +0.00% | 820.8M | 6.14 | A$0.10 | N/A |
| CUV.AX | A$10.39 | +4.00% | 521.8M | 16.06 | A$0.64 | +0.48% |
| RAC.AX | A$2.21 | +0.00% | 437.2M | -107.73 | -A$0.02 | N/A |
| SPL.AX | A$0.71 | +1.44% | 292.5M | 110.32 | A$0.01 | N/A |
Stock Comparison
PAB.AX vs CSL.AX Comparison July 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 12.6M. In comparison, CSL.AX has a market cap of 55.3B. Regarding current trading prices, PAB.AX is priced at A$0.04, while CSL.AX trades at A$114.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -3.12, whereas CSL.AX's P/E ratio is 12.41. In terms of profitability, PAB.AX's ROE is -4.06%, compared to CSL.AX's ROE of +0.08%. Regarding short-term risk, PAB.AX is less volatile compared to CSL.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check CSL.AX's competition here
PAB.AX vs TLX.AX Comparison July 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 12.6M. In comparison, TLX.AX has a market cap of 5.5B. Regarding current trading prices, PAB.AX is priced at A$0.04, while TLX.AX trades at A$16.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -3.12, whereas TLX.AX's P/E ratio is -583.54. In terms of profitability, PAB.AX's ROE is -4.06%, compared to TLX.AX's ROE of -0.02%. Regarding short-term risk, PAB.AX is less volatile compared to TLX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check TLX.AX's competition here
PAB.AX vs MSB.AX Comparison July 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 12.6M. In comparison, MSB.AX has a market cap of 2.5B. Regarding current trading prices, PAB.AX is priced at A$0.04, while MSB.AX trades at A$1.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -3.12, whereas MSB.AX's P/E ratio is -13.11. In terms of profitability, PAB.AX's ROE is -4.06%, compared to MSB.AX's ROE of -0.14%. Regarding short-term risk, PAB.AX is less volatile compared to MSB.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check MSB.AX's competition here
PAB.AX vs NEU.AX Comparison July 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 12.6M. In comparison, NEU.AX has a market cap of 2.1B. Regarding current trading prices, PAB.AX is priced at A$0.04, while NEU.AX trades at A$17.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -3.12, whereas NEU.AX's P/E ratio is 70.67. In terms of profitability, PAB.AX's ROE is -4.06%, compared to NEU.AX's ROE of +0.09%. Regarding short-term risk, PAB.AX is less volatile compared to NEU.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check NEU.AX's competition here
PAB.AX vs PYC.AX Comparison July 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 12.6M. In comparison, PYC.AX has a market cap of 962M. Regarding current trading prices, PAB.AX is priced at A$0.04, while PYC.AX trades at A$1.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -3.12, whereas PYC.AX's P/E ratio is -36.18. In terms of profitability, PAB.AX's ROE is -4.06%, compared to PYC.AX's ROE of -0.30%. Regarding short-term risk, PAB.AX is less volatile compared to PYC.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check PYC.AX's competition here
PAB.AX vs OPT.AX Comparison July 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 12.6M. In comparison, OPT.AX has a market cap of 820.8M. Regarding current trading prices, PAB.AX is priced at A$0.04, while OPT.AX trades at A$0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -3.12, whereas OPT.AX's P/E ratio is 6.14. In terms of profitability, PAB.AX's ROE is -4.06%, compared to OPT.AX's ROE of +0.44%. Regarding short-term risk, PAB.AX is less volatile compared to OPT.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check OPT.AX's competition here
PAB.AX vs CUV.AX Comparison July 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 12.6M. In comparison, CUV.AX has a market cap of 521.8M. Regarding current trading prices, PAB.AX is priced at A$0.04, while CUV.AX trades at A$10.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -3.12, whereas CUV.AX's P/E ratio is 16.06. In terms of profitability, PAB.AX's ROE is -4.06%, compared to CUV.AX's ROE of +0.13%. Regarding short-term risk, PAB.AX is less volatile compared to CUV.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check CUV.AX's competition here
PAB.AX vs RAC.AX Comparison July 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 12.6M. In comparison, RAC.AX has a market cap of 437.2M. Regarding current trading prices, PAB.AX is priced at A$0.04, while RAC.AX trades at A$2.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -3.12, whereas RAC.AX's P/E ratio is -107.73. In terms of profitability, PAB.AX's ROE is -4.06%, compared to RAC.AX's ROE of -0.47%. Regarding short-term risk, PAB.AX is less volatile compared to RAC.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check RAC.AX's competition here
PAB.AX vs SPL.AX Comparison July 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 12.6M. In comparison, SPL.AX has a market cap of 292.5M. Regarding current trading prices, PAB.AX is priced at A$0.04, while SPL.AX trades at A$0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -3.12, whereas SPL.AX's P/E ratio is 110.32. In terms of profitability, PAB.AX's ROE is -4.06%, compared to SPL.AX's ROE of -0.16%. Regarding short-term risk, PAB.AX is less volatile compared to SPL.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check SPL.AX's competition here
PAB.AX vs OCC.AX Comparison July 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 12.6M. In comparison, OCC.AX has a market cap of 161M. Regarding current trading prices, PAB.AX is priced at A$0.04, while OCC.AX trades at A$0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -3.12, whereas OCC.AX's P/E ratio is -26.85. In terms of profitability, PAB.AX's ROE is -4.06%, compared to OCC.AX's ROE of -0.45%. Regarding short-term risk, PAB.AX is less volatile compared to OCC.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check OCC.AX's competition here
PAB.AX vs DXB.AX Comparison July 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 12.6M. In comparison, DXB.AX has a market cap of 126.1M. Regarding current trading prices, PAB.AX is priced at A$0.04, while DXB.AX trades at A$0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -3.12, whereas DXB.AX's P/E ratio is -4.21. In terms of profitability, PAB.AX's ROE is -4.06%, compared to DXB.AX's ROE of -2.79%. Regarding short-term risk, PAB.AX is less volatile compared to DXB.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check DXB.AX's competition here
PAB.AX vs ATH.AX Comparison July 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 12.6M. In comparison, ATH.AX has a market cap of 124M. Regarding current trading prices, PAB.AX is priced at A$0.04, while ATH.AX trades at A$0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -3.12, whereas ATH.AX's P/E ratio is -335.29. In terms of profitability, PAB.AX's ROE is -4.06%, compared to ATH.AX's ROE of -0.30%. Regarding short-term risk, PAB.AX is less volatile compared to ATH.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check ATH.AX's competition here
PAB.AX vs RCE.AX Comparison July 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 12.6M. In comparison, RCE.AX has a market cap of 121.5M. Regarding current trading prices, PAB.AX is priced at A$0.04, while RCE.AX trades at A$0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -3.12, whereas RCE.AX's P/E ratio is -4.61. In terms of profitability, PAB.AX's ROE is -4.06%, compared to RCE.AX's ROE of +2.79%. Regarding short-term risk, PAB.AX is less volatile compared to RCE.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check RCE.AX's competition here
PAB.AX vs ACW.AX Comparison July 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 12.6M. In comparison, ACW.AX has a market cap of 115.2M. Regarding current trading prices, PAB.AX is priced at A$0.04, while ACW.AX trades at A$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -3.12, whereas ACW.AX's P/E ratio is -5.38. In terms of profitability, PAB.AX's ROE is -4.06%, compared to ACW.AX's ROE of -1.34%. Regarding short-term risk, PAB.AX is less volatile compared to ACW.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check ACW.AX's competition here
PAB.AX vs PAA.AX Comparison July 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 12.6M. In comparison, PAA.AX has a market cap of 111.9M. Regarding current trading prices, PAB.AX is priced at A$0.04, while PAA.AX trades at A$0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -3.12, whereas PAA.AX's P/E ratio is -11.50. In terms of profitability, PAB.AX's ROE is -4.06%, compared to PAA.AX's ROE of -1.28%. Regarding short-term risk, PAB.AX is less volatile compared to PAA.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check PAA.AX's competition here
PAB.AX vs ILA.AX Comparison July 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 12.6M. In comparison, ILA.AX has a market cap of 95M. Regarding current trading prices, PAB.AX is priced at A$0.04, while ILA.AX trades at A$0.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -3.12, whereas ILA.AX's P/E ratio is -12.18. In terms of profitability, PAB.AX's ROE is -4.06%, compared to ILA.AX's ROE of -1.01%. Regarding short-term risk, PAB.AX is less volatile compared to ILA.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check ILA.AX's competition here
PAB.AX vs ATX.AX Comparison July 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 12.6M. In comparison, ATX.AX has a market cap of 77M. Regarding current trading prices, PAB.AX is priced at A$0.04, while ATX.AX trades at A$0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -3.12, whereas ATX.AX's P/E ratio is -8.67. In terms of profitability, PAB.AX's ROE is -4.06%, compared to ATX.AX's ROE of -0.19%. Regarding short-term risk, PAB.AX is less volatile compared to ATX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check ATX.AX's competition here
PAB.AX vs ALA.AX Comparison July 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 12.6M. In comparison, ALA.AX has a market cap of 76.2M. Regarding current trading prices, PAB.AX is priced at A$0.04, while ALA.AX trades at A$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -3.12, whereas ALA.AX's P/E ratio is -8.86. In terms of profitability, PAB.AX's ROE is -4.06%, compared to ALA.AX's ROE of -0.41%. Regarding short-term risk, PAB.AX is less volatile compared to ALA.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check ALA.AX's competition here
PAB.AX vs IMM.AX Comparison July 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 12.6M. In comparison, IMM.AX has a market cap of 73.7M. Regarding current trading prices, PAB.AX is priced at A$0.04, while IMM.AX trades at A$0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -3.12, whereas IMM.AX's P/E ratio is -0.87. In terms of profitability, PAB.AX's ROE is -4.06%, compared to IMM.AX's ROE of -0.69%. Regarding short-term risk, PAB.AX is less volatile compared to IMM.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check IMM.AX's competition here
PAB.AX vs PAR.AX Comparison July 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 12.6M. In comparison, PAR.AX has a market cap of 71.5M. Regarding current trading prices, PAB.AX is priced at A$0.04, while PAR.AX trades at A$0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -3.12, whereas PAR.AX's P/E ratio is -2.26. In terms of profitability, PAB.AX's ROE is -4.06%, compared to PAR.AX's ROE of -2.66%. Regarding short-term risk, PAB.AX is less volatile compared to PAR.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check PAR.AX's competition here
PAB.AX vs PTX.AX Comparison July 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 12.6M. In comparison, PTX.AX has a market cap of 66.2M. Regarding current trading prices, PAB.AX is priced at A$0.04, while PTX.AX trades at A$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -3.12, whereas PTX.AX's P/E ratio is -6.93. In terms of profitability, PAB.AX's ROE is -4.06%, compared to PTX.AX's ROE of -0.62%. Regarding short-term risk, PAB.AX is less volatile compared to PTX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check PTX.AX's competition here
PAB.AX vs AVE.AX Comparison July 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 12.6M. In comparison, AVE.AX has a market cap of 59.3M. Regarding current trading prices, PAB.AX is priced at A$0.04, while AVE.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -3.12, whereas AVE.AX's P/E ratio is -14.08. In terms of profitability, PAB.AX's ROE is -4.06%, compared to AVE.AX's ROE of -3.70%. Regarding short-term risk, PAB.AX is less volatile compared to AVE.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check AVE.AX's competition here
PAB.AX vs BIO.AX Comparison July 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 12.6M. In comparison, BIO.AX has a market cap of 54.7M. Regarding current trading prices, PAB.AX is priced at A$0.04, while BIO.AX trades at A$0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -3.12, whereas BIO.AX's P/E ratio is 57.14. In terms of profitability, PAB.AX's ROE is -4.06%, compared to BIO.AX's ROE of +0.18%. Regarding short-term risk, PAB.AX is less volatile compared to BIO.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check BIO.AX's competition here
PAB.AX vs ENP.AX Comparison July 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 12.6M. In comparison, ENP.AX has a market cap of 49M. Regarding current trading prices, PAB.AX is priced at A$0.04, while ENP.AX trades at A$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -3.12, whereas ENP.AX's P/E ratio is N/A. In terms of profitability, PAB.AX's ROE is -4.06%, compared to ENP.AX's ROE of -1.05%. Regarding short-term risk, PAB.AX is less volatile compared to ENP.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check ENP.AX's competition here
PAB.AX vs RAD.AX Comparison July 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 12.6M. In comparison, RAD.AX has a market cap of 44.9M. Regarding current trading prices, PAB.AX is priced at A$0.04, while RAD.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -3.12, whereas RAD.AX's P/E ratio is -0.92. In terms of profitability, PAB.AX's ROE is -4.06%, compared to RAD.AX's ROE of -0.93%. Regarding short-term risk, PAB.AX is less volatile compared to RAD.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check RAD.AX's competition here
PAB.AX vs IMU.AX Comparison July 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 12.6M. In comparison, IMU.AX has a market cap of 41.2M. Regarding current trading prices, PAB.AX is priced at A$0.04, while IMU.AX trades at A$0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -3.12, whereas IMU.AX's P/E ratio is -0.73. In terms of profitability, PAB.AX's ROE is -4.06%, compared to IMU.AX's ROE of -1.35%. Regarding short-term risk, PAB.AX is less volatile compared to IMU.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check IMU.AX's competition here
PAB.AX vs BOT.AX Comparison July 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 12.6M. In comparison, BOT.AX has a market cap of 39.8M. Regarding current trading prices, PAB.AX is priced at A$0.04, while BOT.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -3.12, whereas BOT.AX's P/E ratio is -0.59. In terms of profitability, PAB.AX's ROE is -4.06%, compared to BOT.AX's ROE of -1.31%. Regarding short-term risk, PAB.AX and BOT.AX have similar daily volatility (0.00).Check BOT.AX's competition here
PAB.AX vs NOX.AX Comparison July 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 12.6M. In comparison, NOX.AX has a market cap of 29.8M. Regarding current trading prices, PAB.AX is priced at A$0.04, while NOX.AX trades at A$0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -3.12, whereas NOX.AX's P/E ratio is -5.17. In terms of profitability, PAB.AX's ROE is -4.06%, compared to NOX.AX's ROE of +25.10%. Regarding short-term risk, PAB.AX is less volatile compared to NOX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check NOX.AX's competition here
PAB.AX vs LCT.AX Comparison July 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 12.6M. In comparison, LCT.AX has a market cap of 24.5M. Regarding current trading prices, PAB.AX is priced at A$0.04, while LCT.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -3.12, whereas LCT.AX's P/E ratio is N/A. In terms of profitability, PAB.AX's ROE is -4.06%, compared to LCT.AX's ROE of -0.62%. Regarding short-term risk, PAB.AX and LCT.AX have similar daily volatility (0.00).Check LCT.AX's competition here
PAB.AX vs NSB.AX Comparison July 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 12.6M. In comparison, NSB.AX has a market cap of 19.1M. Regarding current trading prices, PAB.AX is priced at A$0.04, while NSB.AX trades at A$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -3.12, whereas NSB.AX's P/E ratio is -3.95. In terms of profitability, PAB.AX's ROE is -4.06%, compared to NSB.AX's ROE of -0.19%. Regarding short-term risk, PAB.AX is less volatile compared to NSB.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check NSB.AX's competition here
PAB.AX vs KZA.AX Comparison July 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 12.6M. In comparison, KZA.AX has a market cap of 18.9M. Regarding current trading prices, PAB.AX is priced at A$0.04, while KZA.AX trades at A$0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -3.12, whereas KZA.AX's P/E ratio is -0.73. In terms of profitability, PAB.AX's ROE is -4.06%, compared to KZA.AX's ROE of -26.34%. Regarding short-term risk, PAB.AX is less volatile compared to KZA.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check KZA.AX's competition here
PAB.AX vs 1AI.AX Comparison July 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 12.6M. In comparison, 1AI.AX has a market cap of 18.8M. Regarding current trading prices, PAB.AX is priced at A$0.04, while 1AI.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -3.12, whereas 1AI.AX's P/E ratio is N/A. In terms of profitability, PAB.AX's ROE is -4.06%, compared to 1AI.AX's ROE of -0.49%. Regarding short-term risk, PAB.AX and 1AI.AX have similar daily volatility (0.00).Check 1AI.AX's competition here
PAB.AX vs NC6.AX Comparison July 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 12.6M. In comparison, NC6.AX has a market cap of 17.5M. Regarding current trading prices, PAB.AX is priced at A$0.04, while NC6.AX trades at A$0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -3.12, whereas NC6.AX's P/E ratio is -6.48. In terms of profitability, PAB.AX's ROE is -4.06%, compared to NC6.AX's ROE of -19.65%. Regarding short-term risk, PAB.AX is less volatile compared to NC6.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check NC6.AX's competition here
PAB.AX vs EZZ.AX Comparison July 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 12.6M. In comparison, EZZ.AX has a market cap of 17.4M. Regarding current trading prices, PAB.AX is priced at A$0.04, while EZZ.AX trades at A$0.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -3.12, whereas EZZ.AX's P/E ratio is 6.04. In terms of profitability, PAB.AX's ROE is -4.06%, compared to EZZ.AX's ROE of +0.10%. Regarding short-term risk, PAB.AX is less volatile compared to EZZ.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check EZZ.AX's competition here
PAB.AX vs MEM.AX Comparison July 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 12.6M. In comparison, MEM.AX has a market cap of 17.1M. Regarding current trading prices, PAB.AX is priced at A$0.04, while MEM.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -3.12, whereas MEM.AX's P/E ratio is -2.86. In terms of profitability, PAB.AX's ROE is -4.06%, compared to MEM.AX's ROE of -0.92%. Regarding short-term risk, PAB.AX is less volatile compared to MEM.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check MEM.AX's competition here
PAB.AX vs BTC.AX Comparison July 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 12.6M. In comparison, BTC.AX has a market cap of 17.1M. Regarding current trading prices, PAB.AX is priced at A$0.04, while BTC.AX trades at A$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -3.12, whereas BTC.AX's P/E ratio is -20.75. In terms of profitability, PAB.AX's ROE is -4.06%, compared to BTC.AX's ROE of -0.10%. Regarding short-term risk, PAB.AX and BTC.AX have similar daily volatility (0.00).Check BTC.AX's competition here
PAB.AX vs MDC.AX Comparison July 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 12.6M. In comparison, MDC.AX has a market cap of 15.1M. Regarding current trading prices, PAB.AX is priced at A$0.04, while MDC.AX trades at A$6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -3.12, whereas MDC.AX's P/E ratio is -7.07. In terms of profitability, PAB.AX's ROE is -4.06%, compared to MDC.AX's ROE of -9.94%. Regarding short-term risk, PAB.AX and MDC.AX have similar daily volatility (0.00).Check MDC.AX's competition here
PAB.AX vs BNO.AX Comparison July 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 12.6M. In comparison, BNO.AX has a market cap of 13.2M. Regarding current trading prices, PAB.AX is priced at A$0.04, while BNO.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -3.12, whereas BNO.AX's P/E ratio is -0.45. In terms of profitability, PAB.AX's ROE is -4.06%, compared to BNO.AX's ROE of +0.47%. Regarding short-term risk, PAB.AX is less volatile compared to BNO.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check BNO.AX's competition here
PAB.AX vs AGN.AX Comparison July 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 12.6M. In comparison, AGN.AX has a market cap of 12.2M. Regarding current trading prices, PAB.AX is priced at A$0.04, while AGN.AX trades at A$0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -3.12, whereas AGN.AX's P/E ratio is -1.25. In terms of profitability, PAB.AX's ROE is -4.06%, compared to AGN.AX's ROE of -1.84%. Regarding short-term risk, PAB.AX is less volatile compared to AGN.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check AGN.AX's competition here
PAB.AX vs CMB.AX Comparison July 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 12.6M. In comparison, CMB.AX has a market cap of 9.7M. Regarding current trading prices, PAB.AX is priced at A$0.04, while CMB.AX trades at A$0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -3.12, whereas CMB.AX's P/E ratio is -6.00. In terms of profitability, PAB.AX's ROE is -4.06%, compared to CMB.AX's ROE of -2.19%. Regarding short-term risk, PAB.AX is less volatile compared to CMB.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check CMB.AX's competition here
PAB.AX vs IMC.AX Comparison July 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 12.6M. In comparison, IMC.AX has a market cap of 9M. Regarding current trading prices, PAB.AX is priced at A$0.04, while IMC.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -3.12, whereas IMC.AX's P/E ratio is -1.87. In terms of profitability, PAB.AX's ROE is -4.06%, compared to IMC.AX's ROE of -0.44%. Regarding short-term risk, PAB.AX and IMC.AX have similar daily volatility (0.00).Check IMC.AX's competition here
PAB.AX vs IXC.AX Comparison July 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 12.6M. In comparison, IXC.AX has a market cap of 6.8M. Regarding current trading prices, PAB.AX is priced at A$0.04, while IXC.AX trades at A$0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -3.12, whereas IXC.AX's P/E ratio is -8.12. In terms of profitability, PAB.AX's ROE is -4.06%, compared to IXC.AX's ROE of -0.17%. Regarding short-term risk, PAB.AX and IXC.AX have similar daily volatility (0.00).Check IXC.AX's competition here
PAB.AX vs VBS.AX Comparison July 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 12.6M. In comparison, VBS.AX has a market cap of 6.7M. Regarding current trading prices, PAB.AX is priced at A$0.04, while VBS.AX trades at A$0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -3.12, whereas VBS.AX's P/E ratio is -4.73. In terms of profitability, PAB.AX's ROE is -4.06%, compared to VBS.AX's ROE of +2.65%. Regarding short-term risk, PAB.AX and VBS.AX have similar daily volatility (0.00).Check VBS.AX's competition here
PAB.AX vs TRP.AX Comparison July 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 12.6M. In comparison, TRP.AX has a market cap of 6M. Regarding current trading prices, PAB.AX is priced at A$0.04, while TRP.AX trades at A$0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -3.12, whereas TRP.AX's P/E ratio is -1.57. In terms of profitability, PAB.AX's ROE is -4.06%, compared to TRP.AX's ROE of -0.30%. Regarding short-term risk, PAB.AX is less volatile compared to TRP.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check TRP.AX's competition here
PAB.AX vs ZLD.AX Comparison July 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 12.6M. In comparison, ZLD.AX has a market cap of 5.9M. Regarding current trading prices, PAB.AX is priced at A$0.04, while ZLD.AX trades at A$0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -3.12, whereas ZLD.AX's P/E ratio is -1.58. In terms of profitability, PAB.AX's ROE is -4.06%, compared to ZLD.AX's ROE of +0.56%. Regarding short-term risk, PAB.AX is less volatile compared to ZLD.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check ZLD.AX's competition here
PAB.AX vs ACR.AX Comparison July 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 12.6M. In comparison, ACR.AX has a market cap of 5.2M. Regarding current trading prices, PAB.AX is priced at A$0.04, while ACR.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -3.12, whereas ACR.AX's P/E ratio is -1.18. In terms of profitability, PAB.AX's ROE is -4.06%, compared to ACR.AX's ROE of -2.12%. Regarding short-term risk, PAB.AX and ACR.AX have similar daily volatility (0.00).Check ACR.AX's competition here
PAB.AX vs BGT.AX Comparison July 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 12.6M. In comparison, BGT.AX has a market cap of 4.6M. Regarding current trading prices, PAB.AX is priced at A$0.04, while BGT.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -3.12, whereas BGT.AX's P/E ratio is -2.39. In terms of profitability, PAB.AX's ROE is -4.06%, compared to BGT.AX's ROE of -1.40%. Regarding short-term risk, PAB.AX is less volatile compared to BGT.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check BGT.AX's competition here
PAB.AX vs RGS.AX Comparison July 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 12.6M. In comparison, RGS.AX has a market cap of 3.7M. Regarding current trading prices, PAB.AX is priced at A$0.04, while RGS.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -3.12, whereas RGS.AX's P/E ratio is -1.20. In terms of profitability, PAB.AX's ROE is -4.06%, compared to RGS.AX's ROE of +4.56%. Regarding short-term risk, PAB.AX is less volatile compared to RGS.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check RGS.AX's competition here
PAB.AX vs BIT.AX Comparison July 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 12.6M. In comparison, BIT.AX has a market cap of 3.3M. Regarding current trading prices, PAB.AX is priced at A$0.04, while BIT.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -3.12, whereas BIT.AX's P/E ratio is -6.06. In terms of profitability, PAB.AX's ROE is -4.06%, compared to BIT.AX's ROE of -1.19%. Regarding short-term risk, PAB.AX and BIT.AX have similar daily volatility (0.00).Check BIT.AX's competition here
PAB.AX vs CYP.AX Comparison July 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 12.6M. In comparison, CYP.AX has a market cap of 2.9M. Regarding current trading prices, PAB.AX is priced at A$0.04, while CYP.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -3.12, whereas CYP.AX's P/E ratio is -0.38. In terms of profitability, PAB.AX's ROE is -4.06%, compared to CYP.AX's ROE of -1.79%. Regarding short-term risk, PAB.AX is less volatile compared to CYP.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check CYP.AX's competition here
PAB.AX vs CHM.AX Comparison July 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 12.6M. In comparison, CHM.AX has a market cap of 2.7M. Regarding current trading prices, PAB.AX is priced at A$0.04, while CHM.AX trades at A$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -3.12, whereas CHM.AX's P/E ratio is -0.19. In terms of profitability, PAB.AX's ROE is -4.06%, compared to CHM.AX's ROE of +28.45%. Regarding short-term risk, PAB.AX is less volatile compared to CHM.AX. This indicates potentially lower risk in terms of short-term price fluctuations for PAB.AX.Check CHM.AX's competition here
PAB.AX vs ANR.AX Comparison July 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 12.6M. In comparison, ANR.AX has a market cap of 2.1M. Regarding current trading prices, PAB.AX is priced at A$0.04, while ANR.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -3.12, whereas ANR.AX's P/E ratio is -1.25. In terms of profitability, PAB.AX's ROE is -4.06%, compared to ANR.AX's ROE of -1.09%. Regarding short-term risk, PAB.AX and ANR.AX have similar daily volatility (0.00).Check ANR.AX's competition here
PAB.AX vs EX1.AX Comparison July 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 12.6M. In comparison, EX1.AX has a market cap of 1.9M. Regarding current trading prices, PAB.AX is priced at A$0.04, while EX1.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -3.12, whereas EX1.AX's P/E ratio is -0.12. In terms of profitability, PAB.AX's ROE is -4.06%, compared to EX1.AX's ROE of -1.10%. Regarding short-term risk, PAB.AX and EX1.AX have similar daily volatility (0.00).Check EX1.AX's competition here
PAB.AX vs 1AD.AX Comparison July 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 12.6M. In comparison, 1AD.AX has a market cap of 1.8M. Regarding current trading prices, PAB.AX is priced at A$0.04, while 1AD.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -3.12, whereas 1AD.AX's P/E ratio is -0.19. In terms of profitability, PAB.AX's ROE is -4.06%, compared to 1AD.AX's ROE of +10.68%. Regarding short-term risk, PAB.AX and 1AD.AX have similar daily volatility (0.00).Check 1AD.AX's competition here
PAB.AX vs HXL.AX Comparison July 2026
PAB.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAB.AX stands at 12.6M. In comparison, HXL.AX has a market cap of 542.9K. Regarding current trading prices, PAB.AX is priced at A$0.04, while HXL.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAB.AX currently has a P/E ratio of -3.12, whereas HXL.AX's P/E ratio is -0.58. In terms of profitability, PAB.AX's ROE is -4.06%, compared to HXL.AX's ROE of -0.32%. Regarding short-term risk, PAB.AX and HXL.AX have similar daily volatility (0.00).Check HXL.AX's competition here